Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Oncology. Found 120 abstracts

no pagination
Davis SN, O'Malley DM, Bator A, Ohman-Strickland P, Clemow L, Ferrante JM, Crabtree BF, Miller SM, Findley P, Hudson SV. Rationale and design of extended cancer education for longer term survivors (EXCELS): a randomized control trial of 'high touch' vs. 'high tech' cancer survivorship self-management tools in primary care. BMC cancer. 2019 Apr 11;19(1):340.   PMCID: PMC6458696
Pakyz AL, Kohinke R, Opper P, Hohmann SF, Jones RM, Nadpara P. High-risk medication use for Clostridium difficile infection among hospitalized patients with cancer. American journal of infection control. 2019 Feb;47(2):217-9.
Reese JB, Lepore SJ, Daly MB, Handorf E, Sorice KA, Porter LS, Tulsky JA, Beach MC. A Brief Intervention to Enhance Breast Cancer Clinicians' Communication about Sexual Health: Feasibility, Acceptability, and Preliminary Outcomes. Psychooncology. 2019 Feb 27;28(4):872-9.   PMCID: PMC6445732
Erkmen CP, Mitchell M, Randhawa S, Sferra S, Kim R, DiSesa V, Kaiser LR, Ma GX. An Enhanced Shared Decision Making Model to Address Willingness and Ability to Undergo Lung Cancer Screening and Follow-Up Treatment in Minority Underserved Populations. J Community Health. 2018 Feb;43(1):27-32.
McIntosh AG, Ristau BT, Ruth K, Jennings R, Ross E, Smaldone MC, Chen DY, Viterbo R, Greenberg RE, Kutikov A, Uzzo RG. Active Surveillance for Localized Renal Masses: Tumor Growth, Delayed Intervention Rates, and >5-yr Clinical Outcomes. Eur Urol. 2018 Aug;74(2):157-64.
Parker DC, Handorf E, Smaldone MC, Uzzo RG, Pitt H, Reese AC. Race and postoperative complications following urologic cancer surgery: An ACS-NSQIP analysis. Urol Oncol. 2017 Dec;35(12):670 e1-670 e6.
Hudson SV, Ohman-Strickland PA, Bator A, O'Malley D, Gundersen D, Lee HS, Crabtree BF, Miller SM. Breast and prostate cancer survivors' experiences of patient-centered cancer follow-up care from primary care physicians and oncologists. J Cancer Surviv. 2016 Mar 31;10(5):906-14.   PMCID: PMC5065009
Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, van Laethem JL, Ottensmeier C, Lopez-Martin JA, Clive S, Joly F, Ray-Coquard I, Dirix L, Machiels JP, Steven N, Reddy M, Hall B, Puchalski TA, Bandekar R, de Velde HV, Tromp B, Vermeulen J, Kurzrock R. A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 2014 Apr;20(8):2192-204.   PMCID: No NIH funds
Bagshaw H, Ruth K, Horwitz EM, Chen DY, Buyyounouski MK. Does family history of prostate cancer affect outcomes following radiotherapy?. Radiotherapy and Oncology. 2014 Feb;110(2):229-34.   PMCID: 3991234
Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente M, Fleming GF, Lim PC, Rubin SC, Katsumata N, Liang SX. Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology. 2014 Apr;32(12):1210-7.   PMCID: PMC3986384
Carlson RW, Larsen JK, McClure J, Fitzgerald L, Venook AP, Benson AB, Anderson BO. International Adaptations of NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2014 May;12(5):643-8.
Coit DG, Thompson JA, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daniels GA, Daud A, DiMaio D, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi S, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Martini MC, Olszanski AJ, Ross MI, Salama A, Swetter SM, Tanabe KK, Trisal V, Urist MM, McMillian NR, Ho M. Melanoma, Version 4.2014 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2014 May;12(5):621-9.   PMCID: No NIH funding
Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD, Demetri GD, Heinrich MC, von Mehren M, Patel S, McCarter MD, Owzar K, DeMatteo RP. Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial. Journal of Clinical Oncology. 2014 May;32(15):1563-70.   PMCID: PMC 4026579
de Bono JS, Piulats JM, Pandha HS, Petrylak DP, Saad F, Aparicio LM, Sandhu SK, Fong P, Gillessen S, Hudes GR, Wang T, Scranton J, Pollak MN. Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 2014 Apr;20(7):1925-34.   PMCID: No NIH funds
Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D, Nccn. Survivorship: Pain Version 1.2014 Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2014 Apr;12(4):488-500.   PMCID: No NIH funds
Denlinger CS, Meropol NJ, Li T, Lewis NL, Engstrom PF, Weiner LM, Cheng JD, Alpaugh RK, Cooper H, Wright JJ, Cohen SJ. A Phase II Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Biliary Tract Cancers. Clinical Colorectal Cancer. 2014 Jun;13(2):81-6.   PMCID: Pmc4189831
Gao WZ, Ma GX, Tan Y, Fang C, Weaver J, Jin M, Lai P, Godwin AK. Culturally Appropriate Education Intervention on Biospecimen Research Participation among Chinese Americans. Cancer Epidemiology Biomarkers & Prevention. 2014 Mar;23(3):383-91.   PMCID: PMC 3955025
Garcia JA, Hudes GR, Choueiri TK, Stadler WM, Wood LS, Gurtler J, Bhatia S, Joshi A, Hozak RR, Xu YH, Schwartz JD, Thompson JA. A Phase 2, Single-Arm Study of Ramucirumab in Patients With Metastatic Renal Cell Carcinoma With Disease Progression on or Intolerance to Tyrosine Kinase Inhibitor Therapy. Cancer. 2014 Jun;120(11):1647-55.   PMCID: No NIH funding
Gowrishankar B, Ibragimova I, Zhou Y, Slifker MJ, Devarajan K, Al-Saleem T, Uzzo RG, Cairns P. MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biology & Therapy. 2014 Mar;15(3):329-41.   PMCID: PMC3974843
Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, Mayer IA, McCormick B, Miller RS, Pegram M, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R, Nccn. Breast Cancer Version 3.2014 Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2014 Apr;12(4):542-90.   PMCID: No NIH funds
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Oncology

Oncology SURVIVAL Primary care CLINICAL-TRIALS OPEN-LABEL CANCER Cancer survivorship GROWTH-FACTOR RECEPTOR TUMOR ANGIOGENESIS Disparity SURVIVORS microRNA EXTERNAL-BEAM RADIATION KRAS MUTATIONS SERUM-LEVELS LUNG-CANCER BEVACIZUMAB THERAPY SUCCINATE-DEHYDROGENASE signatures IGF-IR Shared decision making Follow-up care KIT GENE Cholangiocarcinoma SOLID TUMORS III TRIAL Tumor growth kinetics RCC GENE-EXPRESSION grade Self-management Screening ADJUVANT RADIOTHERAPY OVARIAN-CANCER cell RCC METASTATIC MELANOMA RENAL-CELL CARCINOMA ANGIOGENESIS KIDNEY CANCER renal cell carcinoma POSTHERPETIC NEURALGIA PLACEBO-CONTROLLED TRIAL BREAST-CANCER IMATINIB MESYLATE PERFORATION Nuclear Medicine & Medical Imaging Radiology RATES PERIPHERAL NEUROPATHY phase 2 NEUROPATHIC PAIN PATHWAYS progression PHASE-II PREVENTION clear Health coaching intervention ramucirumab DIAGNOSED MULTIPLE-MYELOMA RESOURCE IN-VIVO SDHA STEM-CELLS Patient-centered care DIFFERENTIATION PROGRAM RECURRENCE OF-THE-LITERATURE Chemotherapeutic agents monoclonal INCREASED SURVIVAL IN-SITU HYBRIDIZATION Prostate cancer SINGLE-AGENT Sexual Behavior Renal mass Delayed intervention GEMCITABINE Cancer CYCLOPHOSPHAMIDE SELECTION Electronic health (eHealth) MEK INHIBITION CASTLEMANS-DISEASE TISSUE metastatic Family history DOXORUBICIN PLUS TUMORS Complications SKIN-SPARING MASTECTOMY GROWTH RNA HUMAN CHOLANGIOCARCINOMA CELLS BOWEL Race Communication Reproductive Health SUNITINIB Breast Neoplasms Active surveillance PROGNOSTIC-SIGNIFICANCE Bortezomib CUTANEOUS Lung cancer SENTINEL-NODE BIOPSY PREDNISONE SORAFENIB KAPPA-B Environmental & Occupational Health Public Renal cell carcinoma EMISSION TOMOGRAPHY BRAF MUTATIONS PROGNOSIS SURGICAL ADJUVANT BREAST Proteosome Clostridium difficile TYROSINE KINASE INTERLEUKIN-6 COMMUNITY OPIOID ASSESSMENT GASTROINTESTINAL PERFORATION FOLLOW-UP PLUS DEXAMETHASONE QUALITY-OF-LIFE ANGIOGENESIS INHIBITOR CARCINOMA Radiotherapy RECURRENT EPITHELIAL OVARIAN RADIATION-THERAPY INTRAHEPATIC CHOLANGIOCARCINOMA COLORECTAL-CANCER PHYSICAL-THERAPY IDENTIFICATION INHIBITORS EXPRESSION HISTOLOGIC TYPES GALLBLADDER CARCINOMA INSULIN CROHNS-DISEASE expression Women's Health ENDOTHELIAL GROWTH-FACTOR TOPICAL AMITRIPTYLINE DISPARITIES Randomized controlled trial COMPUTED TOMOGRAPHY RANDOMIZED CONTROLLED-TRIAL PROGNOSTIC-FACTORS CELL
Last updated on Friday, December 06, 2019